Get the Stockscreener App
31.40
0.16%
-0.05
Pre-market:
31.55
0.15
+0.48%
Royalty Pharma Plc stock is traded at $31.40, with a volume of 3.35M.
It is down -0.16% in the last 24 hours and up +21.94% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$31.45
Open:
$31.62
24h Volume:
3.35M
Relative Volume:
0.97
Market Cap:
$13.95B
Revenue:
$2.27B
Net Income/Loss:
$1.15B
P/E Ratio:
12.31
EPS:
2.55
Net Cash Flow:
$2.80B
1W Performance:
-0.60%
1M Performance:
+21.94%
6M Performance:
+15.87%
1Y Performance:
+4.01%
1-Day Range:
$31.23
$31.62
1-Week Range:
$31.03
$31.68
52-Week Range:
$24.05
$32.21
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
31.40 | 13.95B | 2.27B | 1.15B | 2.80B | 2.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Royalty Pharma (RPRX) to Release Earnings on Tuesday - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Inlet Private Wealth LLC Increases Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Stock Position Lifted by China Universal Asset Management Co. Ltd. - MarketBeat
BlackRock, Inc.'s Strategic Acquisition of Royalty Pharma PLC Sh - GuruFocus.com
Mediolanum International Funds Ltd Has $3.55 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Paragon Capital Management Inc. Increases Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by Robeco Institutional Asset Management B.V. - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Manning & Napier Advisors LLC - MarketBeat
Kearns & Associates LLC Makes New $451,000 Investment in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Swedbank AB Raises Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Royalty Pharma stock gains on MorphoSys bonds sale (RPRX) - Seeking Alpha
Royalty Pharma (RPRX) Announces Sale of MorphoSys Development Funding Bonds - StreetInsider.com
Royalty Pharma Closes Sale of MorphoSys Development Funding Bonds -January 29, 2025 at 09:40 am EST - Marketscreener.com
Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds - EIN News
Subdued Growth No Barrier To Royalty Pharma plc (NASDAQ:RPRX) With Shares Advancing 25% - Simply Wall St
Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025 - Marketscreener.com
Trend Tracker for (RPRX) - Stock Traders Daily
Royalty Pharma Earnings: Strategic Timing Ahead of Market Open Reveals Key Financial Insights - StockTitan
Royalty Pharma (NASDAQ:RPRX) Reaches New 52-Week HighWhat's Next? - MarketBeat
1834 Investment Advisors Co. Buys Shares of 9,500 Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Assenagon Asset Management S.A. Purchases Shares of 19,068 Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Assenagon Asset Management S.A. Makes New Investment in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Impact Partnership Wealth LLC Purchases Shares of 18,323 Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Why Is Andreas Halvorsen Bullish On Royalty Pharma plc (RPRX) Now? - Insider Monkey
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst - Benzinga
Wall Street Analysts Predict a 31.15% Upside in Royalty Pharma (RPRX): Here's What You Should Know - Yahoo Finance
Overbrook Management Corp Has $3.02 Million Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Ascendis and Royalty Pharma enter into $150M royalty funding agreement - MSN
Where are the Opportunities in (RPRX) - Stock Traders Daily
14 Best 52-Week High Stocks To Buy According to Analysts - Insider Monkey
Royalty Pharma plc (RPRX): Analysts Recommend This 52-Week High Stocks Now - Insider Monkey
Royalty Pharma: Key Strategic Updates To Be Priced In - Seeking Alpha
Investors Purchase High Volume of Royalty Pharma Call Options (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (RPRX) 2900 contracts of July 32.50 calls trade - StreetInsider.com
Pallas Capital Advisors LLC Invests $2.36 Million in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (RPRX) Crossed Above the 200-Day Moving Average: What That Means for Investors - Yahoo Finance
Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.22 - Simply Wall St
Royalty Pharma (NASDAQ:RPRX) Has Announced That It Will Be Increasing Its Dividend To $0.22 - Yahoo Finance
Nordea Investment Management AB Decreases Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc authorizes a Buyback Plan. - Marketscreener.com
Did Royalty Pharma (RPRX) Close Shortened Trading Week Higher? - MSN
Here’s Why Royalty Pharma plc (RPRX) Led This Week’s Rally - Insider Monkey
These 10 Firms Led This Week’s Rally - Insider Monkey
Royalty Pharma plc (NASDAQ:RPRX) Receives $41.67 Consensus PT from Analysts - MarketBeat
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):